Abstract: An object of the present invention is to provide a terahertz oscillator that does not have an MIM capacitor structure of which producing is intricacy, and oscillates due to resonance of an RTD and stabilizing resistors. The present invention is a terahertz oscillator, wherein a slot antenna having a slot is formed between a first electrode plate and a second electrode plate which are applied a bias voltage, stabilizing resistors to respectively connect to the first electrode plate and the second electrode plate are provided in the slot, an RTD is provided on the second electrode plate through a mesa, and a conductive material member to form an air bridge between the first electrode plate and the mesa is provided, and wherein an oscillation in a terahertz frequency band is obtained due to a resonance of the RTD and the stabilizing resistors.

Abstract: An object of the present invention is to provide a terahertz oscillator that does not have an MIM capacitor structure of which producing is intricacy, and oscillates due to resonance of an RTD and stabilizing resistors. The present invention is a terahertz oscillator, wherein a slot antenna having a slot is formed between a first electrode plate and a second electrode plate which are applied a bias voltage, stabilizing resistors to respectively connect to the first electrode plate and the second electrode plate are provided in the slot, an RTD is provided on the second electrode plate through a mesa, and a conductive material member to form an air bridge between the first electrode plate and the mesa is provided, and wherein an oscillation in a terahertz frequency band is obtained due to a resonance of the RTD and the stabilizing resistors.

Abstract: The present invention is the sub-carrier modulated terahertz radar that modulates a main-carrier signal in the terahertz frequency band, which is generated from a resonant tunneling diode (RTD), by a sub-carrier signal in a gigahertz frequency band whose frequency varies periodically, irradiates a frequency-modulated irradiation light to a target, detects and demodulates a reflected light from the target, mixes a demodulated signal with the sub-carrier signal, performs a Fourier transform on a mixed signal, and measures a distance from an irradiation position to the target by using a Fourier-transformed frequency signal.

Abstract: A small-size high-power terahertz oscillator achieves a stable oscillation in a terahertz frequency band even at room temperature. The high-power terahertz oscillator has a structure in which a bow-tie antenna is disposed on a substrate, a cavity resonator, which includes two cavities, is disposed at a power supply portion of the bow-tie antenna, and a resonant tunneling diode (RTD) is disposed along a bottom of a wall of the cavity resonator, which defines the two cavities, and stably oscillates waves in the terahertz frequency band at room temperature by using the RTD, the bow-tie antenna and the cavity resonator.

Abstract: [Problem] An object of the present invention is to provide a small-size high-power terahertz oscillator that achieves a stable oscillation in a terahertz frequency band even at a room temperature. [Means for solving the problem] The present invention is the high-power terahertz oscillator that has a structure in which a bow-tie antenna is disposed on a substrate, a cavity resonator which includes two cavities is disposed at a power supply portion of the bow-tie antenna and a RTD is disposed along a bottom of a wall of the cavity resonator which defines the two cavities, and stably oscillates waves in the terahertz frequency band at room temperature by using the RTD, the bow-tie antenna and the cavity resonator.

Abstract: The present invention is the sub-carrier modulated terahertz radar that modulates a main-carrier signal in the terahertz frequency band, which is generated from a resonant tunneling diode (RTD), by a sub-carrier signal in a gigahertz frequency band whose frequency varies periodically, irradiates a frequency-modulated irradiation light to a target, detects and demodulates a reflected light from the target, mixes a demodulated signal with the sub-carrier signal, performs a Fourier transform on a mixed signal, and measures a distance from an irradiation position to the target by using a Fourier-transformed frequency signal.

Abstract: A small-sized frequency-variable terahertz oscillator has a successive and large frequency-sweeping width even at a room temperature. The frequency-variable terahertz oscillator includes a slot antenna, a resonant tunneling diode and a varactor diode arranged parallel to each other along the slot antenna. The frequency-variable terahertz oscillator oscillates in a terahertz frequency range when the resonant tunneling diode and the varactor diode are separately applied with a direct voltage.

Abstract: A small-sized frequency-variable terahertz oscillator has a successive and large frequency-sweeping width even at a room temperature. The frequency-variable terahertz oscillator includes a slot antenna, a resonant tunneling diode and a varactor diode arranged parallel to each other along the slot antenna. The frequency-variable terahertz oscillator oscillates in a terahertz frequency range when the resonant tunneling diode and the varactor diode are separately applied with a direct voltage.

Abstract: Using betaKlotho or a substance that increases or inhibits betaKlotho activity as an agent for controlling the activity of FGF21 mediated by an FGF receptor, the present invention provides a pharmaceutical composition comprising such betaKlotho or such substance as an active ingredient, particularly, a pharmaceutical composition for anti-metabolic syndrome, and further particularly, a pharmaceutical composition for therapeutic or preventive use associated with the control of blood glucose level. In addition, the present invention provides a screening system for each of a substance that enhances or suppresses betaKlotho activity, an FGF21-like active substance, and a betaKlotho-like active substance, which uses a cell system that has expressed an FGF receptor and/or betaKlotho on the surface thereof.

Abstract: A hair removing agent or a hair growth inhibiting agent is provided by determining an endogenous factor having a hair growth inhibitory activity, screening for substances having an activity similar to that of the endogenous factor or substances enhancing the activity or expression of the endogenous factor, and utilizing the physiological activities of such substances. It has been found that FGF18 inhibits hair growth. A method of screening for FGF18-like active substances, substances that promote the activity of FGF18 or substances that promote the expression of FGF18 to thereby obtain candidates for the hair growth inhibiting agent or hair removing agent is disclosed. Also disclosed is a hair growth inhibiting agent or a hair removing agent comprising, as an active ingredient, FGF18 and/or an FGF18 partial peptide, or an FGF18-like active substance and/or a substance that promotes the activity or expression of FGF18 (e.g., Digenea simplex extract).

Abstract: There is provided an FGF2 substitute-containing medicinal composition which comprises, as an active ingredient, a chimeric protein comprising the amino acid sequence of an FGF1 protein in which a partial sequence including a sequence of at least positions 62-83 within a sequence of positions 41-83 is substituted with a partial sequence at the corresponding positions in the amino acid sequence of an FGF2 protein; and the remaining region is formed of the amino acid sequence of FGF1. In particular, this medicinal composition is used for wound healing and for the prevention and treatment of radiation-induced damage, and it exhibits a pharmacological action superior to that of an FGF2 medicinal composition, and further, it can be easily formulated into a preparation.

Abstract: The laser device has a gain medium, first and second clads sandwiching the gain medium in the thickness direction, and a cavity structure for resonating the electromagnetic wave generated in the gain medium. The gain medium includes a plurality of active regions for generating an electromagnetic wave and at lease one connecting region sandwiched among the active regions. The first and second clads are each formed of a negative permittivity medium having a permittivity the real part of which is negative relative to the electromagnetic wave. A potential-adjusting portion is arranged between the connecting region and the first clad and between the connecting region and the second clad for adjusting the electric potential of the connecting region.

Abstract: An oscillation device has a resonant tunneling diode formed by interposing a gain medium including a first barrier layer, a quantum well layer and a second barrier layer between a first thickness adjusting layer and a second thickness adjusting layer. The oscillation device also has a switch for switching the polarity of a bias voltage being applied to the resonant tunneling diode. The first thickness adjusting layer and the second thickness adjusting layer have different thicknesses. Thus, a single oscillation device is driven to oscillate with different oscillation frequencies.

Abstract: A terahertz oscillation device includes a first electrode placed on the semiconductor substrate; a second electrode placed via the insulating layer toward the first electrode, and opposes the first electrode to be placed on the semiconductor substrate; a MIM reflector formed between the first electrode and the second electrode by sandwiching the insulating layer; a resonator adjoining of the MIM reflector and is placed between the first electrode and the second electrode which oppose on the semiconductor substrate; an active element placed at the substantially central part of the resonator; a waveguide adjoining of the resonator and is placed between the first electrode and the second electrode which oppose on the semiconductor substrate; and a horn apertural area adjoining of the waveguide and is placed between the first electrode and the second electrode which oppose on the semiconductor substrate.

Abstract: Disclosed is a mutant protein having an altered fibroblast growth factor receptor specificity, which is produced by deleting one or more amino acid residues from the N-terminus of the amino acid sequence of naturally secreted fibroblast growth factor 18. The protein mutant can be used in a pharmaceutical composition for regulating hair regeneration or growth or a pharmaceutical composition for regulating bone or cartilage formation.

Abstract: The laser device has a gain medium, first and second clads sandwiching the gain medium in the thickness direction, and a cavity structure for resonating the electromagnetic wave generated in the gain medium. The gain medium includes a plurality of active regions for generating an electromagnetic wave and at lease one connecting region sandwiched among the active regions. The first and second clads are each formed of a negative permittivity medium having a permittivity the real part of which is negative relative to the electromagnetic wave. A potential-adjusting portion is arranged between the connecting region and the first clad and between the connecting region and the second clad for adjusting the electric potential of the connecting region.

Abstract: The laser device has a gain medium, first and second clads sandwiching the gain medium in the thickness direction, and a cavity structure for resonating the electromagnetic wave generated in the gain medium. The gain medium includes a plurality of active regions for generating an electromagnetic wave and at lease one connecting region sandwiched among the active regions. The first and second clads are each formed of a negative permittivity medium having a permittivity the real part of which is negative relative to the electromagnetic wave. A potential-adjusting portion is arranged between the connecting region and the first clad and between the connecting region and the second clad for adjusting the electric potential of the connecting region.

Abstract: There is provided an FGF2 substitute containing medicinal composition which comprises, as an active ingredient, a chimeric protein comprising the amino acid sequence of an FGF1 protein in which a partial sequence including a sequence of at least positions 62-83 within a sequence of positions 41-83 is substituted with a partial sequence at the corresponding positions in the amino acid sequence of an FGF2 protein; and the remaining region is formed of the amino acid sequence of FGF1. In particular, this medicinal composition is used for wound healing and for the prevention and treatment of radiation-induced damage, and it exhibits a pharmacological action superior to that of an FGF2 medicinal composition, and further, it can be easily formulated into a preparation.

Abstract: It is intended to provide a hair growth promoting agent, hair regrowth promoting agent or therapeutic for alopecia by determining an endogenous factor that inhibits hair growth and screening for substances that inhibit the activity or expression of the endogenous factor. It has been found that FGF18 inhibits hair growth. A method of screening for substances that inhibit the activity of FGF18 or substances that inhibit the expression of FGF18 to thereby obtain candidates for the hair growth promoting agent, hair regrowth promoting agent or therapeutic for alopecia is disclosed. Also disclosed is a hair growth promoting agent, hair regrowth promoting agent or therapeutic for alopecia comprising, as an active ingredient(s), a substance that inhibit the activity of FGF18 and/or a substance that inhibits the expression of FGF18 such as a partial peptide of FGF18 or a Momordica charantia hot water extract.

Abstract: Using betaKlotho or a substance that increases or inhibits betaKlotho activity as an agent for controlling the activity of FGF21 mediated by an FGF receptor, the present invention provides a pharmaceutical composition comprising such betaKlotho or such substance as an active ingredient, particularly, a pharmaceutical composition for anti-metabolic syndrome, and further particularly, a pharmaceutical composition for therapeutic or preventive use associated with the control of blood glucose level. In addition, the present invention provides a screening system for each of a substance that enhances or suppresses betaKlotho activity, an FGF21-like active substance, and a betaKlotho-like active substance, which uses a cell system that has expressed an FGF receptor and/or betaKlotho on the surface thereof.